Among Sensex constituents, Bajaj Finance led losers, rising 1.35% to Rs 1001.15. Eternal dropped 0.86%, while Sun Pharma, Bajaj Finserv and Bharti Airtel declined 0.53%, 0.34% and 0.29%, respectively.
Five stocks, namely Reliance Industries (RIL), ICICI Bank, Sun Pharma, IndiGo, and Hindustan Unilever, contributed heavily to the Sensex’s decline.
Five stocks, namely HDFC Bank, Sun Pharma, Bharti Airtel, L&T and M&M, contributed heavily to the Sensex’s fall.
Sun Pharma stock slipped 3.23% per cent to Rs 1736.95 against the previous close of Rs 1795.10.
"We are pleased with the ruling issued by the US District Court, as it validates SPARC's long held position on this matter," SPARC CEO Anil Raghavan said in the statement.
SPARC: The stock jumped 20 per cent to touch its upper price band of Rs 161.10, although it remains down 19.73 per cent on a year-to-date (YTD) basis.
Stocks including Orkla India, RBL Bank, TCS, Sun Pharma, Grasim, Britannia, Paytm, IndiGo, Zydus Life, Adani Energy, GRSE and more will be in the spotlight on Thursday, November 06.
On Tuesday, November 4, State Bank of India (SBI), the country’s largest lender, takes centre stage. Investors will keenly assess its asset quality and credit growth trends to gauge the sector’s health.
Wall Street ended mixed overnight, with two of three major US indices closing in red. The Dow Jones Industrial Average slipped 0.16 per cent to settle at 47,632.
Aurobindo Pharma derives 89 per cent of its revenue from exports, with nearly half (49 per cent) from the US. Similarly, Biocon earns about 46 per cent of its revenue from the American market.
This will be the second biggest deal in the pharma sector ever after Sun Pharmaceutical Industries’ 2015 acquisition of Ranbaxy Laboratories.





